Amgen Inc. share price today

(AMGN)

Amgen Inc. share price is $272.58 & ₹23,071.99 as on 7 Dec 2024, 2.30 'hrs' IST

$272.58

▲

-1.75

(-0.64%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Amgen Inc. share price in Dollar and Rupees. Guide to invest in Amgen Inc. from India. Also see the sentimental analysis on Indian investors investing in Amgen Inc.. Get details on the Indian mutual funds that are investing in Amgen Inc.. Get Analyst recommendations and forecasts along with all the Amgen Inc.'s financials.

Amgen Inc. share price movements

$271.72
$274.45
$272.58
0.32%
Downside
Day's Volatility :0.99%
Upside
0.68%
$257.80
$346.85
$272.58
5.42%
Downside
52 Weeks Volatility :25.67%
Upside
21.41%

Amgen Inc. Returns

Period	Amgen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-15.83%	-5.7%	18.0%
6 Months	-9.97%	-0.9%	15.0%
1 Year	1.94%	10.0%	37.4%
3 Years	28.47%	9.3%	25.6%

Amgen Inc. Key Statistics

in dollars & INR

Previous Close	$274.33
Open	$275.01
Today's High	$274.45
Today's Low	$271.72
Market Capitalization	$149.6B
Today's Volume	$3.0M
52 Week High	$346.85
52 Week Low	$257.8
Revenue TTM	$32.5B
EBITDA	$12.2B
Earnings Per Share (EPS)	$7.82
PE Ratio	35.08
Dividend Yield	3.23%
Profit Margin	13.0%
Quarterly Earnings Growth YOY	0.62%
Return On Equity TTM	55.72%

How to invest in Amgen Inc. from India?

It is very easy for Indian residents to invest directly in Amgen Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amgen Inc. stock in both rupees (INR) and dollars (USD). Search for Amgen Inc. or AMGN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amgen Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amgen Inc. shares which would translate to 0.003 fractional shares of Amgen Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Amgen Inc.

408.57%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Investment in Amgen Inc. from India has grown in the last 30 days as on Dec 7, 2024. 408.57% more purchase transactions for Amgen Inc. in the last 30 days versus the previous period.

159%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Amgen Inc. on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 159% more investors are searching Amgen Inc. in the last 30 days versus the previous period.

Indian Mutual Funds that own Amgen Inc.

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	752	112.24	1.29%
Motilal Oswal S&P 500 Index Fund Direct Growth	4618	0.51	0.29%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	6962	12.32	1.14%

Global Institutional Holdings in Amgen Inc.

Vanguard Group Inc
9.74%
BlackRock Inc
8.57%
State Street Corp
5.45%
Morgan Stanley - Brokerage Accounts
2.73%
PRIMECAP Management Company
2.65%
Geode Capital Management, LLC
2.26%

Analyst Recommendation on Amgen Inc.

Buy

56%Buy

35%Hold

8%Sell

Based on 37 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)

Based on 37 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amgen Inc.

What analysts predicted

Upside of 20.48%

Current:

$272.58

Target:

$328.39

Insights on Amgen Inc.

Increasing Revenue
Amgen Inc. has shown positive revenue growth over the last three quarters. The revenue increased from $7.39 billion to $8.50 billion, with an average growth rate of 6.6% per quarter.
Increasing Net Profit
Amgen Inc. has shown a strong performance in its net profit over the past three quarters. The net profit has increased significantly from a loss of $113.0 million to $2.83 billion. This represents an average growth rate of 94.4% in net profit each quarter.
Vs LLY
In the last 1 year, Eli Lilly And Company has given 40.3% return, outperforming this stock by 39.2%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 236.8% return, outperforming this stock by 207.0%

Amgen Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$23.7B	↑ 3.93%
Net Income	$8.4B	↑ 324.15%
Net Profit Margin	35.35%	↑ 26.69%

	FY19	Y/Y Change
Revenue	$23.4B	↓ 1.62%
Net Income	$7.8B	↓ 6.58%
Net Profit Margin	33.57%	↓ 1.78%

	FY20	Y/Y Change
Revenue	$25.4B	↑ 8.83%
Net Income	$7.3B	↓ 7.37%
Net Profit Margin	28.57%	↓ 5.0%

	FY21	Y/Y Change
Revenue	$26.0B	↑ 2.18%
Net Income	$5.9B	↓ 18.87%
Net Profit Margin	22.68%	↓ 5.89%

	FY22	Y/Y Change
Revenue	$26.3B	↑ 1.32%
Net Income	$6.6B	↑ 11.18%
Net Profit Margin	24.89%	↑ 2.21%

	FY23	Y/Y Change
Revenue	$28.2B	↑ 7.09%
Net Income	$6.7B	↑ 2.52%
Net Profit Margin	23.83%	↓ 1.06%

	Q2 FY23	Q/Q Change
Revenue	$7.0B	↑ 14.43%
Net Income	$1.4B	↓ 51.46%
Net Profit Margin	19.74%	↓ 26.8%

	Q3 FY23	Q/Q Change
Revenue	$6.9B	↓ 1.19%
Net Income	$1.7B	↑ 25.45%
Net Profit Margin	25.06%	↑ 5.32%

	Q4 FY23	Q/Q Change
Revenue	$8.2B	↑ 18.73%
Net Income	$767.0M	↓ 55.66%
Net Profit Margin	9.36%	↓ 15.7%

	Q1 FY24	Q/Q Change
Revenue	$7.4B	↓ 9.76%
Net Income	$-113.0M	↓ 114.73%
Net Profit Margin	-1.53%	↓ 10.89%

	Q2 FY24	Q/Q Change
Revenue	$8.3B	↑ 12.67%
Net Income	$746.0M	↓ 760.18%
Net Profit Margin	8.95%	↑ 10.48%

	Q3 FY24	Q/Q Change
Revenue	$8.5B	↑ 2.04%
Net Income	$2.8B	↑ 279.36%
Net Profit Margin	33.28%	↑ 24.33%

	FY18	Y/Y Change
Total Assets	$66.4B	↓ 16.93%
Total Liabilities	$53.9B	↓ 1.46%

	FY19	Y/Y Change
Total Assets	$59.7B	↓ 10.1%
Total Liabilities	$50.0B	↓ 7.2%

	FY20	Y/Y Change
Total Assets	$62.9B	↑ 5.43%
Total Liabilities	$53.5B	↑ 7.01%

	FY21	Y/Y Change
Total Assets	$61.2B	↓ 2.83%
Total Liabilities	$54.5B	↑ 1.73%

	FY22	Y/Y Change
Total Assets	$65.1B	↑ 6.47%
Total Liabilities	$61.5B	↑ 12.84%

	FY23	Y/Y Change
Total Assets	$97.2B	↑ 49.19%
Total Liabilities	$90.9B	↑ 47.94%

	Q2 FY23	Q/Q Change
Total Assets	$90.3B	↑ 1.75%
Total Liabilities	$83.5B	↑ 0.14%

	Q3 FY23	Q/Q Change
Total Assets	$90.5B	↑ 0.29%
Total Liabilities	$82.9B	↓ 0.73%

	Q4 FY23	Q/Q Change
Total Assets	$97.2B	↑ 7.31%
Total Liabilities	$90.9B	↑ 9.71%

	Q1 FY24	Q/Q Change
Total Assets	$93.0B	↓ 4.3%
Total Liabilities	$88.0B	↓ 3.26%

	Q2 FY24	Q/Q Change
Total Assets	$90.9B	↓ 2.23%
Total Liabilities	$85.0B	↓ 3.38%

	Q3 FY24	Q/Q Change
Total Assets	$90.9B	↓ 0.03%
Total Liabilities	$83.4B	↓ 1.91%

	FY18	Y/Y Change
Operating Cash Flow	$11.3B	↑ 1.06%
Investing Cash Flow	$14.3B	↓ 456.34%
Financing Cash Flow	$-22.5B	↑ 241.07%

	FY19	Y/Y Change
Operating Cash Flow	$9.2B	↓ 19.0%
Investing Cash Flow	$5.7B	↓ 60.19%
Financing Cash Flow	$-15.8B	↓ 29.89%

	FY20	Y/Y Change
Operating Cash Flow	$10.5B	↑ 14.72%
Investing Cash Flow	$-5.4B	↓ 194.61%
Financing Cash Flow	$-4.9B	↓ 69.13%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↓ 11.77%
Investing Cash Flow	$733.0M	↓ 113.57%
Financing Cash Flow	$-8.3B	↑ 69.94%

	FY22	Y/Y Change
Operating Cash Flow	$9.7B	↑ 4.97%
Investing Cash Flow	$-6.0B	↓ 924.56%
Financing Cash Flow	$-4.0B	↓ 51.19%

	FY23	Y/Y Change
Operating Cash Flow	$8.5B	↓ 12.86%
Investing Cash Flow	$-26.2B	↑ 333.55%
Financing Cash Flow	$21.0B	↓ 621.38%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$4.1B	↑ 286.18%
Investing Cash Flow	$-211.0M	↓ 115.54%
Financing Cash Flow	$-1.2B	↓ 105.63%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$2.8B	↓ 32.83%
Investing Cash Flow	$-262.0M	↑ 24.17%
Financing Cash Flow	$-2.0B	↑ 65.7%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$538.0M	↓ 80.51%
Investing Cash Flow	$-27.1B	↑ 10239.31%
Financing Cash Flow	$2.8B	↓ 237.36%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$689.0M	↑ 28.07%
Investing Cash Flow	$-217.0M	↓ 99.2%
Financing Cash Flow	$-1.7B	↓ 162.02%

Amgen Inc. Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Amgen Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amgen Inc.	-14.75%	-9.97%	1.94%	28.47%	17.83%
Eli Lilly And Company	3.53%	-4.55%	38.05%	237.93%	586.64%
Johnson & Johnson	-4.6%	1.62%	-3.17%	-9.02%	6.42%
Merck & Co. Inc.	2.35%	-21.25%	-0.19%	41.44%	16.72%
Novo Nordisk A/s	1.11%	-24.24%	12.6%	91.91%	283.91%
Abbvie Inc	-12.14%	3.35%	18.01%	44.56%	103.81%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amgen Inc.	35.08	35.08	1.97	19.58	0.56	0.05	0.03	14.0
Eli Lilly And Company	89.26	89.26	0.78	13.16	0.65	0.14	0.01	15.83
Johnson & Johnson	25.65	25.65	0.92	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	21.18	21.18	0.07	7.75	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.03	34.03	1.63	22.7	0.89	0.21	0.01	27.07
Abbvie Inc	63.74	63.74	0.44	10.93	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amgen Inc.	Buy	$149.6B	17.83%	35.08	13.0%
Eli Lilly And Company	Buy	$746.3B	586.64%	89.26	20.48%
Johnson & Johnson	Buy	$373.6B	6.42%	25.65	16.74%
Merck & Co. Inc.	Buy	$261.9B	16.72%	21.18	19.23%
Novo Nordisk A/s	Buy	$472.8B	283.91%	34.03	35.01%
Abbvie Inc	Buy	$323.5B	103.81%	63.74	9.22%

Amgen Inc. Dividend announcements

Amgen Inc. Dividends December, 2024
In the quarter ending December,2024. Amgen Inc. has declared dividend of $2.25
Read More

About Amgen Inc.

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Organization	Amgen Inc.
Employees	26700
CEO	Mr. Robert A. Bradway
Industry	Health Technology

Management People of Amgen Inc.

Name	Title
Mr. Robert A. Bradway	Chairman, CEO & President
Mr. Peter H. Griffith	Executive VP & CFO
Mr. Esteban Santos	Executive Vice President of Operations
Dr. David M. Reese M.D.	Executive VP & CTO
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance
Dr. James E. Bradner M.D.	Executive VP of Research & Development and Chief Scientific Officer
Mr. Scott Skellenger	Senior VP & Chief Information Officer
Justin G. Claeys	Vice President of Investor Relations
Mr. Jonathan P. Graham J.D.	Executive VP, General Counsel & Secretary

Important FAQs about investing in Amgen Inc. from India :

What is Amgen Inc. share price today?

Amgen Inc. (AMGN) share price today is $272.58.

Can Indians buy Amgen Inc. shares?

Yes, Indians can invest in the Amgen Inc. (AMGN) from India.

With INDmoney, you can buy Amgen Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amgen Inc. at zero transaction cost.

How can I buy Amgen Inc. shares from India?

It is very easy to buy Amgen Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amgen Inc. be purchased?

Yes, you can buy fractional shares of Amgen Inc. with INDmoney app.

What are the documents required to start investing in Amgen Inc. stocks?

To start investing in Amgen Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.